PS
Top 1% — Elite
Patrick Soon-Shiong
Los Angeles, South Africa
55 H-Index
6,053 Citations
567 Total Impact
Overview
Patrick Soon-Shiong is a oncology specialist at NantHealth. Based in South Africa.
For Patients
- Pioneered the Abraxane (nab-paclitaxel), a technique still used by doctors worldwide
- Research is cited 6K+ times by other doctors and scientists
- Currently at NantHealth in Los Angeles, South Africa
Biography
Patrick Soon-Shiong is a South African-American surgeon and biotech entrepreneur who developed Abraxane, a nanoparticle albumin-bound paclitaxel that improved cancer treatment. Also pioneered one of the first whole-organ pancreas transplants.
Affiliations & Institutions
Research Impact
10 Publications
6,053 Total Citations
5K+ Citation Milestone
Publication Timeline
Published In
Clinical Cancer ResearchJournal of Clinical OncologyAdvanced Drug Delivery ReviewsThe LancetPubMed
Key Publications
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.
Gemcitabine Plus<i>nab</i>-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Protein nanoparticles as drug carriers in clinical medicine
Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Areas of Expertise
Pioneering Techniques
Medical Specialties
Clinical Knowledge & Procedures
Legacy Timeline
The life and contributions of Patrick Soon-Shiong
2005
FDA approved Abraxane
Nanoparticle albumin-bound paclitaxel approved for breast cancer treatment